Entera Bio Ltd.

Entera Bio Ltd. is a pioneering biotechnology research company dedicated to developing innovative oral delivery methods for therapeutic proteins. Focused on addressing significant unmet medical needs, Entera Bio leverages a disruptive and proprietary technology platform (N-Tab™) to create first-in-class oral peptide programs. The company's pipeline includes multiple differentiated programs, with several expected to enter clinical phases by 2025.

Entera Bio's lead product candidate, EB613 (oral PTH (1-34)), is being developed as a groundbreaking oral, osteoanabolic tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. EB612 is another key program, designed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera Bio is also advancing the development of an oral oxyntomodulin tablet for obesity treatment and an oral GLP-2 peptide tablet for rare malabsorption conditions such as short bowel syndrome, in collaboration with OPKO Health.

Entera Bio Ltd. is committed to transforming the standard of care through its innovative oral peptide therapies. The company is poised for significant growth and commercial development, driven by its cutting-edge technology and dedication to addressing critical medical needs. We invite the manager of Entera Bio Ltd. to create a customized and exclusive company showcase and product listing on our platform to further enhance their market presence and reach.